Personalized medicine: Reality and reality checks

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 963-966

  Leeder, J Steven ^a   Spielberg, Stephen P ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Cost benefit analysis; Personalized medicine; Pharmacogenomics

Indexed keywords

ELECTRONIC MEDICAL RECORD; GENERAL PRACTITIONER; HEALTH CARE COST; INTERVENTION STUDY; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL INFORMATION; NOTE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL;

DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GENOMICS; HEALTH CARE COSTS; HUMANS; PHARMACOGENETICS;

EID: 65749087825     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M065     Document Type: Note

References (13)

1. Deloitte Development LLC, Center for Health Solutions. www.deloitte. com/dtt/article/0%2C1002%2Ccid%25253D242167%2C00.html (accessed 2009 Jan 28).
2. Keckley PH, Dhar A, Underwood HR. The ROI for targeted therapies: a strategic perspective. Washington, DC: Deloitte Center for Health Solutions, 2009. www.deloitte.com/dtt/cda/doc/content/us-chs-ROIforTargeted Therapies-January2009%281%29.pdf (accessed 2009 Jan 29).
3. Dean CE. Personalized medicine: boon or budget buster? Ann Pharmacother 2009;43:958-962 Epub 5 May 2009. DOI 10.1345/aph.1L563
4. Martin P, Lewis G, Smart A, Webster A. False positive? The commercial and clinical development of pharmacogenetics. 2006. www.york.ac.uk/res/ pgx/publications/FalsePositive2006.pdf (accessed 2009 Feb 2).
5. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 2008;456:728-731
6. Hindorff LA, Junkins HA, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. www.genome.gov/26525384 (accessed 2009 Feb 2).
7. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009;150:65-72.
8. Morrow EM, Yoo SY, Flavell SW, et al. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008;321:218-223
9. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881-888
10. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 2008;299:1574-1587
11. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
12. Ioannidis JPA. Personalized genetic prediction: too limited, too expensive, or too soon? Ann Intern Med 2009;150:139-141
13. Douglas FL, Mitchell L. Assessing risk and return: personalized medicine development & new innovation paradigm. Kansas City: Ewing Marion Kauffman Foundation, 2008. www.kauffman.org/uploadedFiles/ HHS-White-Paper-1008.pdf (accessed 2009 Feb 3).